SCHEMBL3012672

SCHEMBL3012672

O=S(=O)(c1cccc(Br)c1)N1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
GBA1 P04062 2/20 0.46
MBTD1 Q05BQ5 1/20 0.42
L3MBTL3 Q96JM7 1/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 3/20 0.39
RAB9A P51151 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP3A4 P08684 1/20 0.39
GRM5 P41594 1/20 0.39
GPR183 P32249 1/20 0.38
HIF1A Q16665 1/20 0.37
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009893 0.95 KMT2A (0.54) KMT2AMEN1GBA1MBTD1L3MBTL3
SCHEMBL3007579 0.93 MEN1 (0.46) KMT2AMEN1GBA1MBTD1L3MBTL3
SCHEMBL3016663 0.93 MEN1 (0.45) KMT2AMEN1GBA1ALDH1A1SMN1; SMN2
SCHEMBL3005390 0.93 SMN1; SMN2 (0.45) KMT2AMEN1GBA1ALDH1A1SMN1; SMN2
SCHEMBL3011602 0.93 SMN1; SMN2 (0.46) KMT2AMEN1GBA1ALDH1A1SMN1; SMN2
SCHEMBL3002653 0.92 MEN1 (0.44) KMT2AMEN1GBA1MBTD1L3MBTL3
SCHEMBL3014383 0.91 MEN1 (0.42) KMT2AMEN1GBA1ALDH1A1SMN1; SMN2
SCHEMBL3017026 0.91 MEN1 (0.44) KMT2AMEN1GBA1MBTD1L3MBTL3
SCHEMBL3009030 0.91 CNR1 (0.43) KMT2AMEN1GBA1ALDH1A1SMN1; SMN2
SCHEMBL3008060 0.91 HTT (0.50) KMT2AMEN1GBA1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.